Companies in #Neurodegenerative Disease
Found 1 company operating in this sector.
Neuphoria Therapeutics is a clinical-stage biopharmaceutical company developing CNS-focused therapeutics for neuropsychiatric and neurodegenerative conditions. The company's lead partnered program MK-1167, an adjunctive Alzheimer's disease therapy being co-developed with Merck under a 2022 partnership, was discontinued in mid-2026 after a planned interim Phase 2 efficacy review. This was the second Merck-Neuphoria compound to be discontinued (MK-4334 was previously shelved in 2022), effectively ending the partnership.